CytoSorbents Corporation (CTSO)

[IL-6]

In regards to Kymriah approval, this is from Q3 2017

We have had a lot of success in treating secondary HLH, which is why we feel very confident that CytoSorb could help treat cytokine release syndrome in CAR-T Cell immunotherapy patients. We envision that CytoSorb can be used after tocilizumab, which is typically first line therapy to treat cytokine release syndrome, but before steroids which has been reported to be used on three quarters of the patients who get severe CRS. The problem with steroids is that it can kill or damage the very expensive CAR-T immunotherapy that costs between $300,000 to $500,000 per treatment. That would obviously be a bad thing.

In terms of usage in Europe, we benefit from the fact that we have had this clinical experience in HLH and are approved to treat cytokine release syndrome and cytokine storm in Europe and other countries where we are selling CytoSorb such as Russia, India, Vietnam, and many other countries. We think that once the approvals for Kymriah and Yescarta spread abroad, we will likely get some fairly rapid usage, particularly in Germany where we have a very strong footprint among most of the major hospitals that would be doing this type of therapy.